Orforglipron UK: Availability, Cost and Side Effects

Orforglipron is an investigational oral GLP-1 receptor agonist developed by Eli Lilly that has generated considerable interest in the UK as a potential once-daily tablet alternative to injectable weight management and type 2 diabetes medicines. Unlike semaglutide or tirzepatide, it is a small-molecule compound requiring no injection. However, orforglipron currently holds no MHRA marketing authorisation and cannot be prescribed or purchased in the UK outside of authorised clinical trials. This article explains how it works, what the trial safety data show, and what options are available now.

What is orforglipron and how does it work?

Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist that mimics the gut hormone GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. It has no UK marketing authorisation and remains in Phase 3 trials.

Orforglipron is an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, marketed in the UK under the brand name Foundayo. Unlike injectable GLP-1 medicines such as semaglutide (Wegovy, Ozempic), or the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide (Mounjaro), orforglipron is a small-molecule compound taken as a daily tablet.

GLP-1 receptor agonists work by mimicking the action of the naturally occurring hormone GLP-1, which is released from the gut after eating. Activating GLP-1 receptors stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite.^[21] These combined effects can lower blood glucose levels and support weight reduction.

Foundayo has received a UK marketing authorisation from the MHRA. Its licensed indications, posology, and full prescribing information are set out in the UK Summary of Product Characteristics (SmPC), which is available on the Electronic Medicines Compendium (emc) at medicines.org.uk. Readers should check the MHRA and EMC for the most current information, as regulatory and commissioning decisions may continue to evolve. Clinical trial data, including Phase 2 and Phase 3 findings, have demonstrated results for both blood glucose control in people with type 2 diabetes and weight reduction in people with obesity; the licensed indications should be confirmed against the current SmPC.^[4][20]

What side effects should I watch out for?

The most commonly reported side effects in trials are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, typically worst at treatment initiation or after dose increases. Severe persistent abdominal pain warrants prompt medical attention due to pancreatitis risk.

The safety profile of orforglipron (Foundayo) is set out in the UK SmPC, which should be read alongside the patient information leaflet (PIL) available on the EMC. The information below is a general patient-facing summary; it does not replace the SmPC or advice from a prescriber or pharmacist.

As with other GLP-1 receptor agonists, the most commonly reported adverse effects in clinical trials have been gastrointestinal in nature, including nausea, vomiting, diarrhoea, and constipation.^[4][20] These effects tend to be most pronounced when starting treatment or after a dose increase, and they often improve over time.

Pancreatitis has been reported in association with the GLP-1 receptor agonist class.^[6][5] Anyone experiencing severe and persistent abdominal pain should seek prompt medical attention by contacting their GP or, if symptoms are severe, calling NHS 111 for urgent advice.

Suspected side effects from Foundayo should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. People who are also participating in a clinical trial involving orforglipron should additionally follow their study protocol for adverse event reporting.

The Foundayo SmPC section 4.6 sets out the guidance on use during pregnancy and breastfeeding; patients should discuss this with their prescriber or pharmacist before starting treatment. Anyone of childbearing potential should ask their prescriber about contraceptive requirements before beginning orforglipron.

What might orforglipron cost in the UK, and will the NHS cover it?

No UK price exists for orforglipron as it holds no MHRA authorisation, and no NICE evaluation or NHS commissioning decision has been made. It cannot be obtained through any prescribing or pharmacy route outside an authorised clinical trial.

Foundayo (orforglipron) has received a UK marketing authorisation from the MHRA, which means it can lawfully be prescribed in the UK. However, MHRA authorisation and NHS funding are separate processes. Before a medicine can be routinely prescribed on the NHS, NICE must evaluate it and issue a technology appraisal recommending its use for specific indications. Local Integrated Care Boards (ICBs) then make commissioning decisions based on that guidance, and for weight-management indications access typically also depends on local specialist pathways and service capacity.^[10][7] As of the time of writing, NICE has not yet published a completed technology appraisal for orforglipron, so NHS availability cannot be confirmed. Readers should check the NICE website and their local ICB for the latest commissioning position.

Private prescribing of Foundayo may be possible where a prescriber considers it clinically appropriate, subject to the usual rules governing prescription-only medicines. A list price has not been confirmed in publicly available sources at the time of writing; readers should check the BNF, the Drug Tariff, or ask their pharmacist for current pricing information once it becomes available.

For context, other oral treatments for type 2 diabetes vary considerably in cost depending on the medicine and formulation, and injectable GLP-1 receptor agonists currently available in the UK are funded by the NHS only within specific criteria set by NICE and local ICBs.

People who are interested in currently available, MHRA-authorised weight management or type 2 diabetes treatments can explore options through their GP or through a GPhC-registered online pharmacy. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support; MHRA-authorised options may be discussed and considered where clinically appropriate following such a consultation.

Is orforglipron available in the UK yet?

Orforglipron is not available in the UK outside of authorised clinical trials and cannot legally be prescribed or supplied through any other route. Those interested in current authorised options should speak to their GP about semaglutide or tirzepatide.

Orforglipron is marketed in the UK under the brand name Foundayo and has received a UK marketing authorisation from the MHRA. This means it can lawfully be prescribed by a registered prescriber where it is clinically appropriate. However, marketing authorisation does not automatically mean a medicine is immediately available at every pharmacy or funded by the NHS. Readers should check with their prescriber or a registered pharmacy for current supply and availability information, and should check the MHRA and manufacturer communications for the latest position on UK launch.

NHS access depends on NICE issuing a positive technology appraisal and local ICBs making commissioning decisions; these steps had not been completed at the time of writing. Until NHS commissioning is confirmed, Foundayo is not routinely available on NHS prescription.

Patients should be cautious of any website or service offering to supply orforglipron or Foundayo without a valid prescription from a registered UK prescriber, or through channels that do not comply with the rules governing prescription-only medicines. Unlawful supply or advertising of prescription medicines is a serious concern; if in doubt, check that any online pharmacy is registered with the GPhC (for pharmacies in Great Britain) at pharmacyregulation.org, or with the PSNI (for pharmacies in Northern Ireland) at psni.org.uk.

Regulatory review processes in other countries are separate from the MHRA's own assessment, and authorisation in one jurisdiction does not automatically result in authorisation in the UK.^[22]

For people who are interested in participating in clinical research involving orforglipron or other medicines, the NHS provides information about ongoing trials through the NIHR Be Part of Research service (bepartofresearch.nihr.ac.uk), and trials can also be searched via clinicaltrials.gov and the ISRCTN registry.

Several other MHRA-authorised medicines are available for the management of type 2 diabetes and chronic weight management in the UK, including semaglutide (Wegovy for weight management, Ozempic for type 2 diabetes) and tirzepatide (Mounjaro, which is authorised both for type 2 diabetes and for chronic weight management).^[14][15] People who feel they may benefit from these treatments should speak to their GP or a registered healthcare provider to discuss whether they are clinically appropriate.

Frequently Asked Questions